Biology:HSD17B13
From HandWiki
Short description: Protein-coding gene in the species Homo sapiens
 Generic protein structure example |
17β-Hydroxysteroid dehydrogenase type 13 also known as 17β-HSD type 13 is an enzyme that in humans is encoded by the HSD17B13 gene.[1][2]
17β-HSD13 is significantly up-regulated in the liver of patients with non-alcoholic fatty liver disease (NAFLD) and enhances lipogenesis.[3]
Inhibitors
In 2023 the first potent and selective HSD17B13 inhibitor, BI-3231, was reported.[4] The inhibitor meets the quality criteria of a 'Donated Chemical Probe' as defined by the Structural Genomics Consortium.[5]
References
- ↑ Zhu, Yuan-Shan; Imperato-McGinley, Julianne L. (9 November 2016). "4.02: Disorders of Sexual Development in Males: Molecular Genetics, Epigenetics, Gender Identity, and Cognition". Hormones, Brain and Behavior. 4: Clinical Important Effects of Hormones on Brain and Behavior. Elsevier Science. pp. 69. ISBN 978-0-12-803608-2. https://books.google.com/books?id=NT8oCwAAQBAJ&pg=RA3-PA69.
- ↑ Zanders, Edward D. (9 November 2015). Human Drug Targets: A Compendium for Pharmaceutical Discovery. John Wiley & Sons. pp. 257–. ISBN 978-1-118-84985-9. https://books.google.com/books?id=airvCQAAQBAJ&pg=PA257.
- ↑ "Comparative proteomic study reveals 17β-HSD13 as a pathogenic protein in nonalcoholic fatty liver disease". Proceedings of the National Academy of Sciences of the United States of America 111 (31): 11437–42. 2014. doi:10.1073/pnas.1410741111. PMID 25028495. Bibcode: 2014PNAS..11111437S.
- ↑ Thamm, Sven; Willwacher, Marina K.; Aspnes, Gary E. et al. (2023). "Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science". Journal of Medicinal Chemistry 66 (4): 2832–2850. doi:10.1021/acs.jmedchem.2c01884. PMID 36727857.
- ↑ "Donated Chemical Probes". https://www.thesgc.org/donated-chemical-probes.
 |  |
